medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2012, Number 4

<< Back Next >>

Rev Esp Med Quir 2012; 17 (4)

Anti-ischemic management of electric burns in children

Moctezuma PLE, Páez FI, Jiménez GS, Miguel JDK, Sevilla BJ, Barrera VO, Melo SE, Hernández GE, Flores AJ, Núñez LV

Language: Spanish
References: 100
Page: 313-324
PDF size: 324.67 Kb.


ABSTRACT

The treatment of electric burns of third and fourth grade of extremities is very complex and difficult; because different tissues are simultaneously damaged with severe local hypoperfusion that if they have not been attended early and properly could require amputation, that’s why their medical attention must be always in burn units since initial stages. In early stages, in addition to providing integral life support, anti-ischemic actions could be done such as the macroscopic reperfusion with early surgical reconstruction, the administration of drugs and the implementation of local medical devices that promote the regeneration of capillaries and other tissues. Once damaged tissue is totally regenerated, the rehabilitation will start. In later stages amputation could be the only choice. The antiischemic measures applied in these children suggest that they could be a sustainable alternative in hospitals that treat burn patients because they: avoid amputations, accelerate healing of difficult wounds, and avoid complications from prolonged hospitalizations. These alternatives are available in Mexican pharmacies with affordable costs. Randomized multicenter clinical trials are required for knowing the efficacy of different anti-ischemic treatments.


REFERENCES

  1. Enoch S, Grey JE, Harding KG. Recent advances and emerging burn treatments. BMJ 2006;332:962-965.

  2. Werner S, Grose R. Regulation of wound healing. Physiol Rev 2003;83:835-870.

  3. Stone S, Levy ML. Practical Guide to Pediatric Wound Care. Semin Plast Surg 2006;20:192-200.

  4. Creager MA, Kaufman JA, Conte MS. Acute limb ischemia. N Engl J Med 2012;366:2198-2206.

  5. Kaiser M, Yafi A, Cinat M, Choi B, Durkin AJ. Noninvasive assessment of burn wound severity using optical technology: A review of current and future modalities. Burns 2011;37:377-386.

  6. Kajdaniuk D, Marek B, Foltyn W, Kos-Kudla B. Vascular endothelial growth factor (VEGF) PART 1: in physiology and pathophysiology. Pol J Endocrinol 2011;62(5):444-455.

  7. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bezacuzimab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-615.

  8. Monstrey SM, Hoeksema H, Baker RD, et al. Burn wound healing time assessed by laser Doppler imaging. Part 2: Validation of a colour code for image interpretatation. Burn 2011;37(2):249-256.

  9. Shupp JW, Nasabzadeh TJ, Rosenthal DS. A review of the local pathophysiologic bases of burn wound progression. J Burn Care Res 2010;31:849-873.

  10. Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in periferial artery disease. Chest 2012;141:669-690.

  11. Ao Q, Wang A, Cao W, et al. Manufacture of multimicrotubule chitosan nerve conduits with novel molds and characterization in vitro. J Biomed Mater Res A 2006;77:11-18.

  12. De Acosta-Andino M. Actualización bibliográfica sobre el uso de preparaciones ricas en plaquetas en la cicatrización de heridas. Cir Plast Iberolatinoam 2010;36(3):231-238.

  13. Mogosanu GD, Popescu FC, Busuioc CJ, Parvanescu H. Natural products locally modulators of the cellular response: therapeutic perspective in skin burns. Rom J Morphol Embryol 2012;53(2):249-262.

  14. Patel M, Mao L, Wu B, Vandevord P. GDNF blended chitosan nerve guides: An in vivo study. J Biomed Mater Res 2009;154-165.

  15. Thomas S. Surgical dressings and wound management. 2nd ed. Hinesburg: Kestrel Health Information, 2012;285-289, 633-650. 16. Alsarra IA. Chitosan topical gel formulation in the management of burns. Int J Biol Macromol 2009;45:16-21.

  16. Colangelo AM, Finotti N, Ceriani M, et al. Recombinant human nerve growth factor with marked activity in vitro and in vivo. Proc Natl Acad Sci USA 2005;102(51):18658-18653.

  17. Dai T, Tanaka M, Huang YY, Hamblin MR. Chitosan preparations for wounds and burns: antimicrobial and wound healing. Expert Rev Anti Infect Ther 2011;9(7):857-879.

  18. Guerra GD, Barbani N, Gagliardi M, Rosellini E, Cristallini C. Chitosan based macromolecular biomaterials for regeneration of chondroskeletal and nerve tissue. Int J Carb Chem 2011:1-9.

  19. Semenza GL. Oxygen sensing, homeostasis and disease. N Engl J Med 2011;365:537-547.

  20. Andrae J, Gallini R, Betsholtz C. Role of platelet derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-1312.

  21. Koria P. Delivery of growth factors for tissue regeneration and wound healing. BioDrugs 2012;26(3):163-175.

  22. Lee K, Silva EA, Mooney DJ. Growth factor delivery based tissue engineering: general approaches and a review of recent development. J R Soc Interface 2011;8:153-170.

  23. Lacci KM, Dardik A. Platelet rich plasma: support for its use in wound healing. J Biol Med 2010;83:1-9.

  24. Rozman P, Bolta Z. Use of platelet growth factor in treating wounds and soft tissue injuries. Acta Dermatoven APA 2007;16(4):156-165.

  25. Andree C, Swain WF, Page CP, et al. In vivo transfer and expression of human epidermal growth factor gene accelerates wound repair. Proc Natl Acad Sci USA 1994;91:12188-12192.

  26. Ching YH, Sutton TL, Pierpont YN, Robson MC, Payne WG. The use of growth factors and other humoral agents to accelerate and enhace burn wound healing. Eplasty 2011;11:429-449.

  27. Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient movilization of VEFG2 endothelial precursors cells. Circ Res 2001;88:167-174.

  28. Butler KL, Goverman J, Ma H, et al. Stem cells and burns: Review and therapeutic implications. J Burn Care Res 2010;31:874-881.

  29. Chade AR. VEFG: potential therapy for renal regeneration. F1000 Medicine Reports 2012;4(1):1-5.

  30. Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcer. Biologics 2008;2(1):1-12.

  31. Pham TN, Gibran NS. Thermal and electrical injuries. Surg Clin North Am 2007;87:185-206.

  32. Flaquer M, Romagnani P, Cruzado JM. Growth factors and renal regeneration. Nefrologia 2010;30(4):385-393.

  33. Fricker FR, Bennett DL. The role of neuroregulin-1 in the response in the nerve injury. Future Neurol 2011;6(6):809-822.

  34. Metcalfe AD, Ferguson MWJ. Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. J R Soc Interface 2007;4:413-437.

  35. Rosenstein JM, Krum JM, Ruhrberg C. VEFG in the nervous system. Organogenesis 2010;6(2):107-114.

  36. Berrios RL, Arviser JL. Novel anti-angiogenic agents in dermatology. Arch Biochem Biophys 2011;508(2):22-226.

  37. Valls MD, Cronstein BN, Montesinos M. Adenosine receptor agonists for promotion of dermal wound healing. Biochem Pharmacol 2009;77(7):1117-1124.

  38. Harris E, Schulzke SM, Patoleet SK. Pentoxyfiline in preterm neonates. Pediatric Drugs 2010;12(6):301-311.

  39. Gauglitz GG, Herndon DN, Jeschke MG. Emergency treatment of severly burn patient patients: current therapies strategies. Pediatr Health 2008;2(6):761-775.

  40. Murphy PS, Evans GRD. Advances in wound healing: A review of current wound healing products. Plast Surg Int 2012;ID190436:1-8.

  41. Clark RA, Ghosh K, Tonnesen MG. Tissue engineering for cutaneous wounds. J Invest Dermatol 2007;127:1018-1029.

  42. Chen ZL, Yu WM, Strickland S. Peripheral regeneration. Annu Rev Neurosci 2007;30:209-233.

  43. Montón-Echeverria J, Pérez-Redondo S, Gómez-Bajo GJ. Experiencia clínica en el empleo de factores de crecimiento autólogos obtenidos de plasma rico en plaquetas. Cir Plast Iberolatinoam 2007;33(3):1551-1562.

  44. Escotto SI, Rodríguez-Trejo SM, Padilla SL, Rodríguez RN. Factores de crecimiento en el tratamiento de úlceras en pacientes diabéticos. Rev Mex Angiol 2001;29(3):75-82.

  45. Hendrick & Westernmark. Mechanism of action and in vivo role of platelet derived growth factor. Physiol Rev 1999;79(4):1284-1316.

  46. Kirsner RS, Warriner R, Michela M, Stasik L, Freeman K. Advanced biological therapies for diabetic foot. Arch Dermatol 2010;146(8):857-862.

  47. Shevchenko RV, James SL. A review of tissue engineered skin bioconstructs available for skin reconstruction. J R Soc Interface 2010;7:229-258.

  48. Tiaka EK, Papanas N, Manolakis A, Maltezos E. The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers. Int J Burn Trauma 2011;1(1):68-76.

  49. Velásquez DA, Pineda C, Cardona M, et al. Soluciones terapéuticas para la reconstrucción de la dermis y epidermis. Oportunidades en el medio antioqueño. Revista Ingeniería Biomédica 2008;2(3):77-83.

  50. Qayyum AA, Haack-Sorensen M, Jorensen E, et al. Adipose derived mesenchymal stromal cells for chronic myocardial ischemia (My Stromal Celltrial): Sudy design. Regen Med 2012;7(3):421-428.

  51. Enoch S, Grey JE, Harding KG. Recent advances and emerging burn treatments. BMJ 2006;332:962-965.

  52. Werner S, Grose R. Regulation of wound healing. Physiol Rev 2003;83:835-870.

  53. Stone S, Levy ML. Practical Guide to Pediatric Wound Care. Semin Plast Surg 2006;20:192-200.

  54. Creager MA, Kaufman JA, Conte MS. Acute limb ischemia. N Engl J Med 2012;366:2198-2206.

  55. Kaiser M, Yafi A, Cinat M, Choi B, Durkin AJ. Noninvasive assessment of burn wound severity using optical technology: A review of current and future modalities. Burns 2011;37:377-386.

  56. Kajdaniuk D, Marek B, Foltyn W, Kos-Kudla B. Vascular endothelial growth factor (VEGF) PART 1: in physiology and pathophysiology. Pol J Endocrinol 2011;62(5):444-455.

  57. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bezacuzimab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-615.

  58. Monstrey SM, Hoeksema H, Baker RD, et al. Burn wound healing time assessed by laser Doppler imaging. Part 2: Validation of a colour code for image interpretatation. Burn 2011;37(2):249-256.

  59. Shupp JW, Nasabzadeh TJ, Rosenthal DS. A review of the local pathophysiologic bases of burn wound progression. J Burn Care Res 2010;31:849-873.

  60. Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in periferial artery disease. Chest 2012;141:669-690.

  61. Ao Q, Wang A, Cao W, et al. Manufacture of multimicrotubule chitosan nerve conduits with novel molds and characterization in vitro. J Biomed Mater Res A 2006;77:11-18.

  62. De Acosta-Andino M. Actualización bibliográfica sobre el uso de preparaciones ricas en plaquetas en la cicatrización de heridas. Cir Plast Iberolatinoam 2010;36(3):231-238.

  63. Mogosanu GD, Popescu FC, Busuioc CJ, Parvanescu H. Natural products locally modulators of the cellular response: therapeutic perspective in skin burns. Rom J Morphol Embryol 2012;53(2):249-262.

  64. Patel M, Mao L, Wu B, Vandevord P. GDNF blended chitosan nerve guides: An in vivo study. J Biomed Mater Res 2009;154-165.

  65. Thomas S. Surgical dressings and wound management. 2nd ed. Hinesburg: Kestrel Health Information, 2012;285-289, 633-650. 16. Alsarra IA. Chitosan topical gel formulation in the management of burns. Int J Biol Macromol 2009;45:16-21.

  66. Colangelo AM, Finotti N, Ceriani M, et al. Recombinant human nerve growth factor with marked activity in vitro and in vivo. Proc Natl Acad Sci USA 2005;102(51):18658-18653.

  67. Dai T, Tanaka M, Huang YY, Hamblin MR. Chitosan preparations for wounds and burns: antimicrobial and wound healing. Expert Rev Anti Infect Ther 2011;9(7):857-879.

  68. Guerra GD, Barbani N, Gagliardi M, Rosellini E, Cristallini C. Chitosan based macromolecular biomaterials for regeneration of chondroskeletal and nerve tissue. Int J Carb Chem 2011:1-9.

  69. Semenza GL. Oxygen sensing, homeostasis and disease. N Engl J Med 2011;365:537-547.

  70. Andrae J, Gallini R, Betsholtz C. Role of platelet derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-1312.

  71. Koria P. Delivery of growth factors for tissue regeneration and wound healing. BioDrugs 2012;26(3):163-175.

  72. Lee K, Silva EA, Mooney DJ. Growth factor delivery based tissue engineering: general approaches and a review of recent development. J R Soc Interface 2011;8:153-170.

  73. Lacci KM, Dardik A. Platelet rich plasma: support for its use in wound healing. J Biol Med 2010;83:1-9.

  74. Rozman P, Bolta Z. Use of platelet growth factor in treating wounds and soft tissue injuries. Acta Dermatoven APA 2007;16(4):156-165.

  75. Andree C, Swain WF, Page CP, et al. In vivo transfer and expression of human epidermal growth factor gene accelerates wound repair. Proc Natl Acad Sci USA 1994;91:12188-12192.

  76. Ching YH, Sutton TL, Pierpont YN, Robson MC, Payne WG. The use of growth factors and other humoral agents to accelerate and enhace burn wound healing. Eplasty 2011;11:429-449.

  77. Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient movilization of VEFG2 endothelial precursors cells. Circ Res 2001;88:167-174.

  78. Butler KL, Goverman J, Ma H, et al. Stem cells and burns: Review and therapeutic implications. J Burn Care Res 2010;31:874-881.

  79. Chade AR. VEFG: potential therapy for renal regeneration. F1000 Medicine Reports 2012;4(1):1-5.

  80. Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcer. Biologics 2008;2(1):1-12.

  81. Pham TN, Gibran NS. Thermal and electrical injuries. Surg Clin North Am 2007;87:185-206.

  82. Flaquer M, Romagnani P, Cruzado JM. Growth factors and renal regeneration. Nefrologia 2010;30(4):385-393.

  83. Fricker FR, Bennett DL. The role of neuroregulin-1 in the response in the nerve injury. Future Neurol 2011;6(6):809-822.

  84. Metcalfe AD, Ferguson MWJ. Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. J R Soc Interface 2007;4:413-437.

  85. Rosenstein JM, Krum JM, Ruhrberg C. VEFG in the nervous system. Organogenesis 2010;6(2):107-114.

  86. Berrios RL, Arviser JL. Novel anti-angiogenic agents in dermatology. Arch Biochem Biophys 2011;508(2):22-226.

  87. Valls MD, Cronstein BN, Montesinos M. Adenosine receptor agonists for promotion of dermal wound healing. Biochem Pharmacol 2009;77(7):1117-1124.

  88. Harris E, Schulzke SM, Patoleet SK. Pentoxyfiline in preterm neonates. Pediatric Drugs 2010;12(6):301-311.

  89. Gauglitz GG, Herndon DN, Jeschke MG. Emergency treatment of severly burn patient patients: current therapies strategies. Pediatr Health 2008;2(6):761-775.

  90. Murphy PS, Evans GRD. Advances in wound healing: A review of current wound healing products. Plast Surg Int 2012;ID190436:1-8.

  91. Clark RA, Ghosh K, Tonnesen MG. Tissue engineering for cutaneous wounds. J Invest Dermatol 2007;127:1018-1029.

  92. Chen ZL, Yu WM, Strickland S. Peripheral regeneration. Annu Rev Neurosci 2007;30:209-233.

  93. Montón-Echeverria J, Pérez-Redondo S, Gómez-Bajo GJ. Experiencia clínica en el empleo de factores de crecimiento autólogos obtenidos de plasma rico en plaquetas. Cir Plast Iberolatinoam 2007;33(3):1551-1562.

  94. Escotto SI, Rodríguez-Trejo SM, Padilla SL, Rodríguez RN. Factores de crecimiento en el tratamiento de úlceras en pacientes diabéticos. Rev Mex Angiol 2001;29(3):75-82.

  95. Hendrick & Westernmark. Mechanism of action and in vivo role of platelet derived growth factor. Physiol Rev 1999;79(4):1284-1316.

  96. Kirsner RS, Warriner R, Michela M, Stasik L, Freeman K. Advanced biological therapies for diabetic foot. Arch Dermatol 2010;146(8):857-862.

  97. Shevchenko RV, James SL. A review of tissue engineered skin bioconstructs available for skin reconstruction. J R Soc Interface 2010;7:229-258.

  98. Tiaka EK, Papanas N, Manolakis A, Maltezos E. The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers. Int J Burn Trauma 2011;1(1):68-76.

  99. Velásquez DA, Pineda C, Cardona M, et al. Soluciones terapéuticas para la reconstrucción de la dermis y epidermis. Oportunidades en el medio antioqueño. Revista Ingeniería Biomédica 2008;2(3):77-83.

  100. Qayyum AA, Haack-Sorensen M, Jorensen E, et al. Adipose derived mesenchymal stromal cells for chronic myocardial ischemia (My Stromal Celltrial): Sudy design. Regen Med 2012;7(3):421-428.




2020     |     www.medigraphic.com